SCHEMBL105701

SCHEMBL105701

COCC(Cc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1)OC(N)=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.75
KDR P35968 20/20 0.75
AXL P30530 2/20 0.75
FLT3 P36888 2/20 0.75
PLK4 O00444 1/20 0.75
MAP4K4 O95819 1/20 0.75
ABL1 P00519 1/20 0.75
LCK P06239 1/20 0.75
FYN P06241 1/20 0.75
LYN P07948 1/20 0.75
HCK P08631 1/20 0.75
PDGFRB P09619 1/20 0.75
BCR P11274 1/20 0.75
SRC P12931 1/20 0.75
ABL2 P42684 1/20 0.75
FRK P42685 1/20 0.75
SYK P43405 1/20 0.75
MST1R Q04912 1/20 0.75
DDR1 Q08345 1/20 0.75
MERTK Q12866 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL105699 0.92 MET (0.71) METKDRAXLFLT3PLK4
SCHEMBL104141 0.86 MET (0.82) METKDRAXLFLT3PLK4
Glesatinib SCHEMBL106319 0.86 MET (1.00) METKDRAXLFLT3PLK4
Glesatinib SCHEMBL29351360 0.86 MET (1.00) METKDRAXLFLT3PLK4
SCHEMBL2536266 0.85 MET (0.89) METKDRAXLFLT3PLK4
SCHEMBL105698 0.84 MET (0.70) METKDRAXLFLT3PLK4
SCHEMBL105700 0.83 MET (0.82) METKDRAXLFLT3PLK4
SCHEMBL2121003 0.83 MET (0.78) METKDRAXLFLT3PLK4
SCHEMBL104578 0.83 MET (0.77) METKDRAXLFLT3PLK4
SCHEMBL3652049 0.83 MET (0.73) METKDRAXLFLT3PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426108-B1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC (CA) 2016-08-10 EP disclosed
EP-2426108-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MethylGene Inc. (CA) 2012-03-07 EP disclosed